GERN - NASDAQ
Geron Corporation
$1.16
-0.85%Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
At a Glance
Live Snapshotgern
Total Non-Current Assets
Last Annual Value
50.27M
3-Year CAGR
69%
5-Year CAGR
-7%
10-Year CAGR
4%
Geron Corporation Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Geron Corporation NASDAQ:GERN | 50.27M | -1.6% | 5.3% | 13.5% | |
 Tyra Biosciences, Inc. NASDAQ:TYRA | 17.16M | 6.5% | 45.4% | N/A | |
 Vir Biotechnology, Inc. NASDAQ:VIR | 488.74M | 13.9% | 4.5% | N/A | |
 Arvinas, Inc. NASDAQ:ARVN | 17.20M | -11.0% | -10.0% | 38.7% | |
 Rezolute, Inc. NASDAQ:RZLT | 4.34M | -38.6% | 47.8% | -3.8% | |
 Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 22.73M | 208.5% | 118.8% | N/A | |
 Savara Inc. NASDAQ:SVRA | 11.82M | 0.6% | 0.4% | -1.9% | |
 Replimune Group, Inc. NASDAQ:REPL | 55.45M | 0.9% | -1.4% | N/A | |
 LENZ Therapeutics, Inc. NASDAQ:LENZ | 13.53M | 62.9% | 307.8% | N/A | |
 ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 272.00K | -55.7% | 25.6% | N/A |
Geron Corporation Fair Value Envelope
Related Guides
Continue your GERN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.